Hong Kong Construction Stock News

REPT BATTERO Energy (SEHK:666) drew investor attention after using Intersolar Europe 2026 to showcase its Wending 320Ah Sodium Cell and Powtrix 6.9MWh Energy Storage System, both designed for long-duration and utility-scale storage needs. See our latest analysis for REPT BATTERO Energy. Against this backdrop of new energy storage products, REPT BATTERO Energy’s recent share price performance has been mixed. The 1-day share price return of 3.59% and the 7-day share price return of 3.12%...

Genertec Universal Medical Group (SEHK:2666) drew investor focus after its annual general meeting on 24 June 2026, where shareholders approved a final dividend of HK$0.36 per share and amendments to the company’s articles of association. See our latest analysis for Genertec Universal Medical Group. At a share price of HK$4.62, Genertec Universal Medical Group has seen short term share price returns pick up, with gains of 3.36% over one day and 5.24% over seven days. However, the 30 day share...

China Shenhua Energy (SEHK:1088) has brought the No. 5 ultra-supercritical coal-fired units at its Dingzhou and Cangdong Phase III projects into commercial operation after completing 168-hour trials under Hebei’s 14th Five-Year Plan. See our latest analysis for China Shenhua Energy. Despite the new ultra supercritical units entering commercial operation, China Shenhua Energy’s share price has been under pressure in the short term, with a 1 month share price return of down 14.13% and a 3 month...

Nona Biosciences, part of HBM Holdings (SEHK:2142), has entered a collaboration with Lonza to co-develop single domain antibody blood brain barrier crossing technology for central nervous system diseases, drawing fresh attention to HBM Holdings stock. See our latest analysis for HBM Holdings. The Lonza partnership has arrived at a time when HBM Holdings’ share price has gained 5.47% in the last day and 13.12% over the past week, yet remains down 21.35% over 90 days. Meanwhile, the 1 year...

Sun Hung Kai Properties (SEHK:16) drew attention after its technology arm SUNeVision secured a major new customer for the MEGA IDC facility, with Phase One occupancy expected to increase from 30% to about 70% and later phases to be accelerated. See our latest analysis for Sun Hung Kai Properties. Recent trading reflects that this SUNeVision contract has arrived during a mixed period for Sun Hung Kai Properties, with the share price at HK$115.3, a 1-day share price return of 1.86%, a...

Event overview: Qatar Airways sale and leaseback deal BOC Aviation (SEHK:2588) drew fresh attention after announcing agreements to purchase three Airbus A350-1000 aircraft from Qatar Airways and lease them back under long term arrangements. The aircraft were delivered in late 2025, and the company classifies the deal as a Qualified Aircraft Leasing Activity and a discloseable transaction under Hong Kong listing rules, which underscores its relevance within sector norms. See our latest...

Sinotruk (Hong Kong) (SEHK:3808) shareholders approved a final dividend at the 29 June 2026 AGM, offering either HK$0.88 or CN¥0.78 per share for the year ended 31 December 2025. See our latest analysis for Sinotruk (Hong Kong). The dividend decision comes as Sinotruk (Hong Kong)'s share price has risen strongly over the year, with a year to date share price return of 49.32%, while the 1 year total shareholder return of 83.71% and 5 year total shareholder return of 276.36% indicate momentum...

JD Health International Inc. ( HKG:6618 ) saw a double-digit share price rise of over 10% in the past couple of months...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). The strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is...

COSCO SHIPPING Ports Limited ( HKG:1199 ), might not be a large cap stock, but it saw significant share price movement...

What changed at NetEase and why it matters for shareholders NetEase (SEHK:9999) recently approved a Third Amended and Restated Memorandum and Articles of Association at its 2026 Annual General Meeting, a governance update that helps frame how investors may view the stock’s latest move. The bylaw changes came shortly after NetEase stock gained 7.32% over the past week, following quarterly earnings of HK$4.03 per share versus an estimated HK$3.42, a 17.77% difference that has drawn fresh...

Legendary Education Group Limited's ( HKG:8195 ) recent earnings report didn't offer any surprises, with the shares...

Despite posting healthy earnings, China High Speed Transmission Equipment Group Co., Ltd.'s ( HKG:658 ) stock has been...

As you might know, China Water Affairs Group Limited ( HKG:855 ) recently reported its full-year numbers. Statutory...

It looks like China Taiping Insurance Holdings Company Limited ( HKG:966 ) is about to go ex-dividend in the next four...

GSMA membership and AI focused network upgrade reshape the China Tower story China Tower (SEHK:788) has joined the GSMA and completed a nationwide upgrade that turns 5.6 million base stations and 2.1 million tower sites into intelligent edge computing hubs for connectivity in the AI era. See our latest analysis for China Tower. Despite the AI focused upgrade and GSMA membership, China Tower’s recent share price momentum has softened, with the stock at HK$9.04 and the 1 month share price...

CITIC (SEHK:267) drew investor attention after its 26 June 2026 AGM, where the company declared a 2025 final dividend of RMB 0.385 per share, payable in either RMB or Hong Kong dollars. See our latest analysis for CITIC. While the 2025 final dividend announcement has focused attention on income, CITIC’s 1 month share price return is down 20.98% and the year to date share price return is down 13%, even as the 5 year total shareholder return of 83.56% points to a much stronger long term...

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...

Country Garden Holdings (SEHK:2007) has reported June contracted sales of about CN¥2.45b, down 13% year-on-year. The company also reported weaker first half sales and its first interest payment under a major offshore debt restructuring. See our latest analysis for Country Garden Holdings. The June sales update and progress on offshore debt restructuring come after a mixed price pattern for Country Garden Holdings, with the share price up 8.67% over one day and 10.59% over seven days, but down...

AGM approvals put Deep Source Holdings in focus Deep Source Holdings (SEHK:990) is back on investors’ radar after shareholders approved new company bye laws, director re elections and refreshed share issue and repurchase mandates at the 30 June Annual General Meeting. See our latest analysis for Deep Source Holdings. Despite the supportive AGM outcome, Deep Source Holdings’ recent trading has been mixed. The 1 day share price return of 7.27% and 7 day share price return of 3.51% stand against...

Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that the first patient has been enrolled in a Phase III trial for Anaprazole Sodium Enteric-coated Tablets in Helicobacter pylori treatment, a development that could influence how investors view the stock. See our latest analysis for Sihuan Pharmaceutical Holdings Group. At a share price of HK$0.89, Sihuan Pharmaceutical Holdings Group has seen a 7-day share price return of 7.23%, but the 90-day share price return is down...